Subhas Chakrabarty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Subhas Chakrabarty has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Guangming Liu
Department of Microbiology, Immunology and Cell Biology, Simmons Cancer Institute, Southern Illinois University, School of Medicine, Springfield, IL
7 shared publicationsXin Hu
Simmons Cancer Institute, Southern Illinois University School of Medicine, Springfield, Illinois
3 shared publicationsMoltira Promkan
Department of Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine and SimmonsCooper Cancer Institute, Springfield, IL 62794-9677, USA
2 shared publicationsNavneet Singh
Department of Microbiology, Immunology and Cell Biology, Simmons Cancer Institute, Southern Illinois University, School of Medicine, Springfield, IL
2 shared publicationsDaotai Nie
1 shared publicationHong Mei Wang
Division of Laboratory Medicine, Box 73 University of Texas M.D. Anderson Cancer Center 1515 Holcombe Boulevard Houston, TX 77030,
1 shared publication
Latest Publications
- Open Access
- 15 May 2013
- Published by Wiley in International Journal of Cancer
- Vol. 133 (10) , 2307-2314
Induction of CaSR expression circumvents the molecular features of malignant CaSR null colon cancer cells
We recently reported on the isolation and characterization of calcium sensing receptor (CaSR) null human colon cancer cells (Singh et al., Int J Cancer 2013; 132: 1996–2005). CaSR null cells possess a myriad of molecular features that are linked to a highly malignant and drug resistant phenotype of colon cancer. The CaSR null phenotype can be maintained in defined human embryonic stem cell culture medium. We now show that the CaSR null cells can be induced to differentiate in conventional culture medium, regained the expression of CaSR with a concurrent reversal of the cellular and molecular features associated with the null phenotype. These features include cellular morphology, expression of colon cancer stem cell markers, expression of survivin and thymidylate synthase and sensitivity to fluorouracil. Other features include the expression of epithelial mesenchymal transition linked molecules and transcription factors, oncogenic miRNAs and tumor suppressive molecule and miRNA. With the exception of cancer stem cell markers, the reversal of molecular features, upon the induction of CaSR expression, is directly linked to the expression and function of CaSR because blocking CaSR induction by shRNA circumvented such reversal. We further report that methylation and demethylation of the CaSR gene promoter underlie CaSR expression. Due to the malignant nature of the CaSR null cells, inclusion of the CaSR null phenotype in disease management may improve on the mortality of this disease. Because CaSR is a robust promoter of differentiation and mediates its action through diverse mechanisms and pathways, inactivation of CaSR may serve as a new paradigm in colon carcinogenesis.
- 15 May 2013
- Published by Wiley in International Journal of Cancer
- Vol. 133 (10) , 2307-2314
Open AccessInduction of CaSR expression circumvents the molecular features of malignant CaSR null colon cancer cells
We recently reported on the isolation and characterization of calcium sensing receptor (CaSR) null human colon cancer cells (Singh et al., Int J Cancer 2013; 132: 1996–2005). CaSR null cells possess a myriad of molecular features that are linked to a highly malignant and drug resistant phenotype of colon cancer. The CaSR null phenotype can be maintained in defined human embryonic stem cell culture medium. We now show that the CaSR null cells can be induced to differentiate in conventional culture medium, regained the expression of CaSR with a concurrent reversal of the cellular and molecular features associated with the null phenotype. These features include cellular morphology, expression of colon cancer stem cell markers, expression of survivin and thymidylate synthase and sensitivity to fluorouracil. Other features include the expression of epithelial mesenchymal transition linked molecules and transcription factors, oncogenic miRNAs and tumor suppressive molecule and miRNA. With the exception of cancer stem cell markers, the reversal of molecular features, upon the induction of CaSR expression, is directly linked to the expression and function of CaSR because blocking CaSR induction by shRNA circumvented such reversal. We further report that methylation and demethylation of the CaSR gene promoter underlie CaSR expression. Due to the malignant nature of the CaSR null cells, inclusion of the CaSR null phenotype in disease management may improve on the mortality of this disease. Because CaSR is a robust promoter of differentiation and mediates its action through diverse mechanisms and pathways, inactivation of CaSR may serve as a new paradigm in colon carcinogenesis.
- Open Access
- 11 October 2012
- Published by Wiley in International Journal of Cancer
- Vol. 132 (9) , 1996-2005
Isolation and characterization of calcium sensing receptor null cells: A highly malignant and drug resistant phenotype of colon cancer
The expression of calcium sensing receptor (CaSR) in the human colonic crypt epithelium is linked to cellular differentiation while its lack of expression is associated with undifferentiated and invasive colon carcinoma. Human colon carcinoma cell lines contain small subpopulations (10–20%) that do not express CaSR (termed CaSR null cells). Here, we report on the isolation, propagation, maintenance and characterization of CaSR null cells from the CBS and HCT116 human colon carcinoma cell lines. CaSR null cells grew as three‐dimensional non‐adherent spherical clusters with increased propensity for anchorage independent growth, cellular proliferation and invasion of matrigels. CaSR null cells were highly resistant to fluorouracil and expressed abundant amount of thymidylate synthase and survivin. Molecular profiling by real time reverse transcription‐polymerase chain reaction (RT‐PCR) and Western blots showed a high level of expression of the previously reported cancer stem cell markers CD133, CD44 and Nanog in CaSR null cells. A significant increase in the expression of epithelial–mesenchymal transitional molecules and transcription factors was also observed. These include N‐cadherin, β‐catenin, vimentin, fibronectin, Snail1, Snail2, Twist and FOXC2. The expression of the tumor suppressive E‐cadherin and miR145, on the other hand, was greatly reduced while expression of the oncogenic microRNAs: miR21, miR135a and miR135b was significantly up‐regulated. CaSR null cells possess a myriad of cellular and molecular features that drive and sustain the malignant phenotype. We conclude that CaSR null constitutes a highly malignant and drug resistant phenotype of colon cancer.
- 11 October 2012
- Published by Wiley in International Journal of Cancer
- Vol. 132 (9) , 1996-2005
Open AccessIsolation and characterization of calcium sensing receptor null cells: A highly malignant and drug resistant phenotype of colon cancer
The expression of calcium sensing receptor (CaSR) in the human colonic crypt epithelium is linked to cellular differentiation while its lack of expression is associated with undifferentiated and invasive colon carcinoma. Human colon carcinoma cell lines contain small subpopulations (10–20%) that do not express CaSR (termed CaSR null cells). Here, we report on the isolation, propagation, maintenance and characterization of CaSR null cells from the CBS and HCT116 human colon carcinoma cell lines. CaSR null cells grew as three‐dimensional non‐adherent spherical clusters with increased propensity for anchorage independent growth, cellular proliferation and invasion of matrigels. CaSR null cells were highly resistant to fluorouracil and expressed abundant amount of thymidylate synthase and survivin. Molecular profiling by real time reverse transcription‐polymerase chain reaction (RT‐PCR) and Western blots showed a high level of expression of the previously reported cancer stem cell markers CD133, CD44 and Nanog in CaSR null cells. A significant increase in the expression of epithelial–mesenchymal transitional molecules and transcription factors was also observed. These include N‐cadherin, β‐catenin, vimentin, fibronectin, Snail1, Snail2, Twist and FOXC2. The expression of the tumor suppressive E‐cadherin and miR145, on the other hand, was greatly reduced while expression of the oncogenic microRNAs: miR21, miR135a and miR135b was significantly up‐regulated. CaSR null cells possess a myriad of cellular and molecular features that drive and sustain the malignant phenotype. We conclude that CaSR null constitutes a highly malignant and drug resistant phenotype of colon cancer.
- 3 March 2011
- Published by Wiley in Molecular Carcinogenesis
- Vol. 50 (12) , 922-930
Nifedipine synergizes with calcium in activating the calcium sensing receptor, suppressing the expression of thymidylate synthase and survivin and promoting sensitivity to fluorouracil in human colon carcinoma cells
We have previously reported that activation of the G protein coupled calcium‐sensing receptor (CaSR) by extracellular Ca2+ down‐modulates the expression of thymidylate synthase (TS) and survivin and promotes sensitivity to fluorouracil in human colon carcinoma cells. Here, we report for the first time that the cardiac drug nifedipine acted synergistically with Ca2+ in CaSR activation and in the induction of intracellular Ca2+. Nifedipine in combination with Ca2+ significantly down‐modulated the expression of TS and survivin and promoted sensitivity to 5‐FU above and beyond the level achievable with Ca2+ alone. Nifedipine by itself, however, had no effect on the suppression of TS or survivin or sensitivity to 5‐FU. The action of Ca2+ or in combination with nifedipine was entirely CaSR dependent as the aforementioned effects did not occur in CaSR knocked down cells. siRNAs targeting TS or survivin or both could mimic the effect of CaSR activation in promoting sensitivity to 5‐FU. We conclude that nifedipine acts in synergy with Ca2+ in activating CaSR and in promoting sensitivity to 5‐FU by down modulating the expression of TS and survivin. G‐protein coupled CaSR has the potential of serving as a target for improving therapeutic outcome in colon cancer.
- 3 March 2011
- Published by Wiley in Molecular Carcinogenesis
- Vol. 50 (12) , 922-930
Nifedipine synergizes with calcium in activating the calcium sensing receptor, suppressing the expression of thymidylate synthase and survivin and promoting sensitivity to fluorouracil in human colon carcinoma cells
We have previously reported that activation of the G protein coupled calcium‐sensing receptor (CaSR) by extracellular Ca2+ down‐modulates the expression of thymidylate synthase (TS) and survivin and promotes sensitivity to fluorouracil in human colon carcinoma cells. Here, we report for the first time that the cardiac drug nifedipine acted synergistically with Ca2+ in CaSR activation and in the induction of intracellular Ca2+. Nifedipine in combination with Ca2+ significantly down‐modulated the expression of TS and survivin and promoted sensitivity to 5‐FU above and beyond the level achievable with Ca2+ alone. Nifedipine by itself, however, had no effect on the suppression of TS or survivin or sensitivity to 5‐FU. The action of Ca2+ or in combination with nifedipine was entirely CaSR dependent as the aforementioned effects did not occur in CaSR knocked down cells. siRNAs targeting TS or survivin or both could mimic the effect of CaSR activation in promoting sensitivity to 5‐FU. We conclude that nifedipine acts in synergy with Ca2+ in activating CaSR and in promoting sensitivity to 5‐FU by down modulating the expression of TS and survivin. G‐protein coupled CaSR has the potential of serving as a target for improving therapeutic outcome in colon cancer.
- 1 January 2010
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 15 (1) , 151-165
Growth factors in tumor microenvironment
Tumor microenvironment plays a critical role in tumor initiation and progression. Components in the microenvironment can modulate the growth of tumor cells, their ability to progress and metastasize. A major venue of communication between tumor cells and their microenvironment is through polypeptide growth factors and receptors for these growth factors. This article discusses three major classes of growth-stimulatory polypeptide growth factors and receptors for these growth factors. It also discusses how deregulation of these growth factors or their receptors can drive malignant transformation and progression.
- 1 January 2010
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 15 (1) , 151-165
Growth factors in tumor microenvironment
Tumor microenvironment plays a critical role in tumor initiation and progression. Components in the microenvironment can modulate the growth of tumor cells, their ability to progress and metastasize. A major venue of communication between tumor cells and their microenvironment is through polypeptide growth factors and receptors for these growth factors. This article discusses three major classes of growth-stimulatory polypeptide growth factors and receptors for these growth factors. It also discusses how deregulation of these growth factors or their receptors can drive malignant transformation and progression.
- Open Access
- 20 July 2009
- Published by Wiley in International Journal of Cancer
- Vol. 126 (3) , 631-639
Vitamin D mediates its action in human colon carcinoma cells in a calcium‐sensing receptor‐dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5‐FU
Vitamin D (VD) protects against colon carcinogenesis by mechanisms not fully understood. We had earlier reported on the similarity in the biologic action of VD and that of the calcium‐sensing receptor (CaSR) in human colon carcinoma cells. At the molecular level, the CaSR gene contains 2 VD response elements and VD stimulates the expression of CaSR. In this study, we investigated on the relationship between VD action and CaSR function. We determined and compared the action of VD in human colon carcinoma cells (CBS, Moser, Caco‐2 and HCT116) and their CaSR knocked‐down counterparts. VD inhibited cellular proliferation, cellular invasion, and anchorage‐independent growth and stimulated the expression of p21/Waf1 but not in CaSR knocked‐down cells. These results demonstrate, for the first time, that the known tumor‐suppressive function of VD requires functional CaSR and knocking down CaSR expression abrogated this function of VD. We recently reported that activation of CaSR in human colon carcinoma cells downregulated the expression of thymidylate synthase (TS) and survivin and promoted a significant increase in sensitivity to cytotoxic drugs. We now demonstrate, for the first time, that VD suppressed the expression of TS and survivin, TS and survivin gene transcriptional activities and promoted a cytotoxic response to 5‐FU in a CaSR‐dependent manner. Ectopic expression of wild‐type CaSR in colon carcinoma cells also inhibited the expression of TS and survivin and enhanced cellular sensitivity to 5‐FU. VD, however, could no longer enhance cellular sensitivity to 5‐FU in cells overexpressing CaSR.
- 20 July 2009
- Published by Wiley in International Journal of Cancer
- Vol. 126 (3) , 631-639
Open AccessVitamin D mediates its action in human colon carcinoma cells in a calcium‐sensing receptor‐dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5‐FU
Vitamin D (VD) protects against colon carcinogenesis by mechanisms not fully understood. We had earlier reported on the similarity in the biologic action of VD and that of the calcium‐sensing receptor (CaSR) in human colon carcinoma cells. At the molecular level, the CaSR gene contains 2 VD response elements and VD stimulates the expression of CaSR. In this study, we investigated on the relationship between VD action and CaSR function. We determined and compared the action of VD in human colon carcinoma cells (CBS, Moser, Caco‐2 and HCT116) and their CaSR knocked‐down counterparts. VD inhibited cellular proliferation, cellular invasion, and anchorage‐independent growth and stimulated the expression of p21/Waf1 but not in CaSR knocked‐down cells. These results demonstrate, for the first time, that the known tumor‐suppressive function of VD requires functional CaSR and knocking down CaSR expression abrogated this function of VD. We recently reported that activation of CaSR in human colon carcinoma cells downregulated the expression of thymidylate synthase (TS) and survivin and promoted a significant increase in sensitivity to cytotoxic drugs. We now demonstrate, for the first time, that VD suppressed the expression of TS and survivin, TS and survivin gene transcriptional activities and promoted a cytotoxic response to 5‐FU in a CaSR‐dependent manner. Ectopic expression of wild‐type CaSR in colon carcinoma cells also inhibited the expression of TS and survivin and enhanced cellular sensitivity to 5‐FU. VD, however, could no longer enhance cellular sensitivity to 5‐FU in cells overexpressing CaSR.
- Open Access
- 23 June 2009
- Published by Wiley in International Journal of Cancer
- Vol. 125 (12) , 2820-2828
BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells
BRCA1 is a multifunctional tumor‐suppressive protein. Many functional aspects of BRCA1 are not fully understood. We used a shRNA approach to probe the function of BRCA1 in human breast cancer cells. Knocking down BRCA1 expression by shRNA in the wild‐type BRCA1 human breast cancer MCF‐7 and MDA‐MB‐231 cells resulted in an increase in cell proliferation, anchorage‐independent growth, cell migration, invasion and a loss of p21/Waf1 and p27Kip1 expression. In BRCA1 knocked‐down cells, the expression of survivin was significantly up regulated with a concurrent decrease in cellular sensitivity to paclitaxel. We also found that cells harboring endogenous mutant or defective BRCA1 (MDA‐MB‐436 and HCC1937) were highly proliferative and expressed a relatively low level of p21/Waf1 and p27Kip1 by comparison to wild‐type BRCA1 cells. Cells harboring mutated BRCA1 also expressed a high level of survivin and were relatively resistant to paclitaxel by comparison to wild‐type cells. Increase resistance to paclitaxel was due to an increase in the expression of survivin in both the BRCA1 knocked‐down and mutant BRCA1 cells because knocking down survivin expression by siRNA restored sensitivity to paclitaxel. We conclude that BRCA1 down‐modulates the malignant behavior of breast cancer cells, promotes the expression of p21/Waf1, p27Kip1 and inhibits the expression of survivin. Moreover, loss of BRCA1 expression or function leads to an increase in survivin expression and a reduction in chemosensitivity to paclitaxel. © 2009 UICC
- 23 June 2009
- Published by Wiley in International Journal of Cancer
- Vol. 125 (12) , 2820-2828
Open AccessBRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells
BRCA1 is a multifunctional tumor‐suppressive protein. Many functional aspects of BRCA1 are not fully understood. We used a shRNA approach to probe the function of BRCA1 in human breast cancer cells. Knocking down BRCA1 expression by shRNA in the wild‐type BRCA1 human breast cancer MCF‐7 and MDA‐MB‐231 cells resulted in an increase in cell proliferation, anchorage‐independent growth, cell migration, invasion and a loss of p21/Waf1 and p27Kip1 expression. In BRCA1 knocked‐down cells, the expression of survivin was significantly up regulated with a concurrent decrease in cellular sensitivity to paclitaxel. We also found that cells harboring endogenous mutant or defective BRCA1 (MDA‐MB‐436 and HCC1937) were highly proliferative and expressed a relatively low level of p21/Waf1 and p27Kip1 by comparison to wild‐type BRCA1 cells. Cells harboring mutated BRCA1 also expressed a high level of survivin and were relatively resistant to paclitaxel by comparison to wild‐type cells. Increase resistance to paclitaxel was due to an increase in the expression of survivin in both the BRCA1 knocked‐down and mutant BRCA1 cells because knocking down survivin expression by siRNA restored sensitivity to paclitaxel. We conclude that BRCA1 down‐modulates the malignant behavior of breast cancer cells, promotes the expression of p21/Waf1, p27Kip1 and inhibits the expression of survivin. Moreover, loss of BRCA1 expression or function leads to an increase in survivin expression and a reduction in chemosensitivity to paclitaxel. © 2009 UICC
- 18 December 2008
- Published by Elsevier in Cancer Letters
- Vol. 272 (2) , 253-259
Switch of transforming growth factor β function from tumor suppression to stimulation in adenomatous polyposis coli (APC) knocked-down human colon carcinoma cells
- 18 December 2008
- Published by Elsevier in Cancer Letters
- Vol. 272 (2) , 253-259
Switch of transforming growth factor β function from tumor suppression to stimulation in adenomatous polyposis coli (APC) knocked-down human colon carcinoma cells
- 10 July 2008
- Published by Wiley in Molecular Carcinogenesis
- Vol. 48 (3) , 202-211
Calcium and calcium sensing receptor modulates the expression of thymidylate synthase, NAD(P)H:quinone oxidoreductase 1 and survivin in human colon carcinoma cells: Promotion of cytotoxic response to mitomycin C and fluorouracil
Ca2+ and the cell‐surface calcium sensing receptor (CaSR) constitute a novel and robust ligand/receptor system in regulating the proliferation and differentiation of colonic epithelial cells. Here we show that activation of CaSR by extracellular Ca2+ (or CaSR agonists) enhanced the sensitivity of human colon carcinoma cells to mitomycin C (MMC) and fluorouracil (5‐FU). Activation of CaSR up‐regulated the expression of MMC activating enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO‐1) and down‐regulated the expression of 5‐FU target, thymidylate synthase (TS) and the anti‐apoptotic protein survivin. Cells that were resistant to drugs expressed little or no CaSR but abundant amount of survivin. Disruption of CaSR expression by shRNA targeting the CaSR abrogated these modulating effects of CaSR activation on the expression of NQO1, TS, survivin and cytotoxic response to drugs. It is concluded that activation of CaSR can enhance colon cancer cell sensitivity to MMC and 5‐FU and can modulate the expression of molecules involved in the cellular responses to these cytotoxic drugs.
- 10 July 2008
- Published by Wiley in Molecular Carcinogenesis
- Vol. 48 (3) , 202-211
Calcium and calcium sensing receptor modulates the expression of thymidylate synthase, NAD(P)H:quinone oxidoreductase 1 and survivin in human colon carcinoma cells: Promotion of cytotoxic response to mitomycin C and fluorouracil
Ca2+ and the cell‐surface calcium sensing receptor (CaSR) constitute a novel and robust ligand/receptor system in regulating the proliferation and differentiation of colonic epithelial cells. Here we show that activation of CaSR by extracellular Ca2+ (or CaSR agonists) enhanced the sensitivity of human colon carcinoma cells to mitomycin C (MMC) and fluorouracil (5‐FU). Activation of CaSR up‐regulated the expression of MMC activating enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO‐1) and down‐regulated the expression of 5‐FU target, thymidylate synthase (TS) and the anti‐apoptotic protein survivin. Cells that were resistant to drugs expressed little or no CaSR but abundant amount of survivin. Disruption of CaSR expression by shRNA targeting the CaSR abrogated these modulating effects of CaSR activation on the expression of NQO1, TS, survivin and cytotoxic response to drugs. It is concluded that activation of CaSR can enhance colon cancer cell sensitivity to MMC and 5‐FU and can modulate the expression of molecules involved in the cellular responses to these cytotoxic drugs.
- 1 June 2008
- Published by Elsevier in Cancer Letters
- Vol. 264 (2) , 281-287
Transforming growth factor β suppresses β-catenin/Wnt signaling and stimulates an adhesion response in human colon carcinoma cells in a Smad4/DPC4 independent manner
- 1 June 2008
- Published by Elsevier in Cancer Letters
- Vol. 264 (2) , 281-287
Transforming growth factor β suppresses β-catenin/Wnt signaling and stimulates an adhesion response in human colon carcinoma cells in a Smad4/DPC4 independent manner
- 1 January 1997
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 2 (4) , d460-470
Action of polypeptide growth factors in colon cancer development of new therapeutic approaches
There has been no significant improvement in the treatment of metastatic colon cancer over the last four decades. A major reason for therapeutic failure is the nonselective nature of conventional chemotherapy. Therefore, new selective therapeutic approaches must be explored to improve survival. Recent advances in cell and molecular biology have opened up new avenues of developing selective molecular therapy for colon cancer. In view of the heterogeneity of cells in colon cancer, it is likely that the use of more than one cellular target will be required to achieve a significant antitumor response. Mechanistic studies of how proliferation, differentiation and malignant properties are controlled by negative growth factors, positive growth factors and adhesion molecules have allowed the identification of several molecular targets of attack in colon cancer. Disruption of one or more of these targets should have a highly antiproliferative and/or cytotoxic effect on colon cancer cells. Additionally, disrupting the expression of these targets may augment sensitivity to conventional chemotherapy. In this article, we will discuss how polypeptide growth factors act in colon cancer cells, identify several molecular targets of attack and discuss strategies for selective disruption of these targets in colon cancer. Where appropriate, the biologic similarities or differences by comparison with other types of tumor will also be discussed.
- 1 January 1997
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 2 (4) , d460-470
Action of polypeptide growth factors in colon cancer development of new therapeutic approaches
There has been no significant improvement in the treatment of metastatic colon cancer over the last four decades. A major reason for therapeutic failure is the nonselective nature of conventional chemotherapy. Therefore, new selective therapeutic approaches must be explored to improve survival. Recent advances in cell and molecular biology have opened up new avenues of developing selective molecular therapy for colon cancer. In view of the heterogeneity of cells in colon cancer, it is likely that the use of more than one cellular target will be required to achieve a significant antitumor response. Mechanistic studies of how proliferation, differentiation and malignant properties are controlled by negative growth factors, positive growth factors and adhesion molecules have allowed the identification of several molecular targets of attack in colon cancer. Disruption of one or more of these targets should have a highly antiproliferative and/or cytotoxic effect on colon cancer cells. Additionally, disrupting the expression of these targets may augment sensitivity to conventional chemotherapy. In this article, we will discuss how polypeptide growth factors act in colon cancer cells, identify several molecular targets of attack and discuss strategies for selective disruption of these targets in colon cancer. Where appropriate, the biologic similarities or differences by comparison with other types of tumor will also be discussed.